Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Inclusion Criteria:

• Capable of giving signed informed consent which includes compliance with therequirements and restrictions listed in the informed consent form (ICF) and in thisprotocol.

• Participants enrolled in any Bayer-sponsored darolutamide feeder study at the timeof study closure or primary completion, who are currently receiving darolutamide andare experiencing clinical benefit from treatment.

• Participants who have not met any treatment discontinuation criteria in the feederstudy protocol.

• Willingness to continue practicing acceptable methods of birth control during thestudy.

Exclusion Criteria:

• Participant is unable to comply with the requirements of the study.

• Negative benefit/ risk ratio as determined by the investigator.

• Meet any criteria for treatment discontinuation of the feeder study the participantis coming from.